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Abstract
Disorders of sexual development (DSD), ranging in severity from genital abnormalities to complete sex reversal, are among
the most common human birth defects with incidence rates reaching almost 3%. Although causative alterations in key
genes controlling gonad development have been identified, the majority of DSD cases remain unexplained. To improve the
diagnosis, we screened 116 children born with idiopathic DSD using a clinically validated array-based comparative genomic
hybridization platform. 8951 controls without urogenital defects were used to compare with our cohort of affected patients.
Clinically relevant imbalances were found in 21.5% of the analyzed patients. Most anomalies (74.2%) evaded detection by
the routinely ordered karyotype and were scattered across the genome in gene-enriched subtelomeric loci. Among these
defects, confirmed de novo duplication and deletion events were noted on 1p36.33, 9p24.3 and 19q12-q13.11 for
ambiguous genitalia, 10p14 and Xq28 for cryptorchidism and 12p13 and 16p11.2 for hypospadias. These variants were
significantly associated with genitourinary defects (P=6.08610
212). The causality of defects observed in 5p15.3, 9p24.3,
22q12.1 and Xq28 was supported by the presence of overlapping chromosomal rearrangements in several unrelated
patients. In addition to known gonad determining genes including SRY and DMRT1, novel candidate genes such as FGFR2,
KANK1, ADCY2 and ZEB2 were encompassed. The identification of risk germline rearrangements for urogenital birth defects
may impact diagnosis and genetic counseling and contribute to the elucidation of the molecular mechanisms underlying
the pathogenesis of human sexual development.
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Introduction
The acquisition of a sexual phenotype depends on critical
embryonic steps, which initially commit the bipotential gonad to
either a testis or an ovary and direct normal morphogenesis of
external genitalia. Disruption of these developmental processes
occurs frequently in humans as reflected by the high prevalence in
newborns of disorders of sexual development (DSD) ranging in
severity from genital abnormalities to complete sex reversal.
Failure of testis descent or cryptorchidism is found in 2% of full-
term males [1]. Hypospadias or defects in the growth and closure
of the external genitalia affect nearly 1 in 125 live male births [2].
Genital phenotypes that are not clearly male or female are
estimated to occur in about 1 of 2000 to 4500 babies [3]. Despite
their incidence, the molecular basis underlying the pathology of
congenital genitourinary (GU) defects is surprisingly poorly
understood. Fetal exposure to environmental toxicants [4,5], as
well as point mutations in a small subset of genes (see for review
[6,7]) can affect human urogenital tract development, but these
known causes do not account for all of the large number of GU
birth defects. Interestingly, as referenced in the Online database of
Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=omim), a significant number of these urogenital
inborn errors are associated with major congenital malformations
or multiple minor anomalies, a trait that is highly suggestive of a
causative chromosomal abnormality. However, routine cytogenet-
ic methods had led to earlier reports of low rates of structural
defects associated with disorders of sexual development [8,9].
The finding that several common syndromes (including mental
retardation, developmental delay and autism) are caused by
specific submicroscopic chromosomal rearrangements, opened up
new avenues for dissecting complex human phenotypes [10,11].
The development of comparative genomic hybridization (CGH)
into a microarray format allowed the identification and diagnosis
of cryptic deletions or duplications of genomic regions that were
once invisible using traditional cytogenetic methods, including
karyotype analysis and fluorescence in situ hybridization (FISH).
Several of these subtle rearrangements occur in regions flanked by
low-copy repeats and likely result from non-allelic homologous
recombination between different copies of these repeats during
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changes of DNA segments and can influence gene expression
levels by directly disrupting genes or regulatory sequences,
creating fusion genes or altering gene dosage. These structural
chromosomal defects can cause disease as occurs in the
microdeletion and microduplication syndromes [12,13,14,15,16]
or confer risk of complex disorders [17,18].
Cryptic chromosomal rearrangements are involved in the
etiology of human reproductive disorders since Y chromosome
microdeletions are associated with human male infertility. Based
on this, we tested the hypothesis that submicroscopic chromosomal
alterations, too small to be detected by routine cytogenetic
methods, may exist in patients with human disorders of sexual
development. We studied probands presenting with hypospadias,
cryptorchidism and ambiguous genitalia, the most common
genital defects seen in pediatric urology clinics. We compared
the resolution of clinical detection of such cryptic abnormalities by
microarray-based chromosomal screening and by the routinely
used karyotype. We further analyzed the contribution of these
structural anomalies to the observed GU phenotypes by studying
their association with the genital traits, as well as their inheritance
and their recurrence. For the first time, findings revealed the
presence of frequent microdeletions and microduplications in the
genome of children born with urogenital disorders and established
de novo germline rearrangements as significant risk factors for
developmental defects of human urogenital tract.
Methods
Ethics Statement, Human Subjects and Sample Collection
This study was approved by the Institutional Review Board
Committee at the Baylor College of Medicine, Houston TX.
Probands affected with unexplained syndromic and non-syndro-
mic congenital genitourinary disorders including hypospadias,
cryptorchidism or ambiguous genitalia were enrolled through
Texas Children’s Hospital and Ben Taub General Hospital,
Houston TX. Known causes of these birth defects such as
anomalies in the synthesis of testosterone or adrenal steroid
hormones or exogenous modifiers were ruled out after examina-
tion by pediatric urologists or neonatologists. Written informed
consents were obtained for infant/child subjects and from their
parents. Blood was collected from the children during surgery for
correction of the GU defects. Parents provided saliva specimens.
Based on the novel CMA findings, additional cases were then
identified through an existing database from Kleberg Cytogenetics
Laboratory (Baylor College of Medicine, Houston TX). These
additional probands were referred patients, mostly presenting with
external genital ambiguity with or without subclinical phenotypes.
Clinical indications at the time of the referral were taken from
crude clinical comments on laboratory requisitions.
CGH based Microarray Analysis (CMA)
High molecular weight genomic DNA isolated from peripheral
blood or saliva was submitted for chromosomal microarray
analysis (CMA) to the Clinical Cytogenetics Laboratory at Baylor
College of Medicine. CMA is a clinically validated targeted CGH
array that covers over 150 distinct human clinically relevant
chromosomal loci [19,20]. Three different versions of CMA have
been used depending on the time of sample submission. The
versions 5 and 6 contain 3 to 10 BAC/PAC clones per genomic
disorder specific locus and subtelomeric regions, with CMA V.5.0
consisting of 853 BAC clones and CMA V.6.1 consisting of 1475
BAC clones with inclusion of 1 clone per band at 650 cytogenetic
banding resolution. The newer version Oligo V.6 uses 42,640
oligonucleotides of 60 base pairs with an average of 20 to 40
oligonucleotides corresponding to each CMA V.6.1 BAC clone
genomic locus. Importantly, data acquired from the array
platforms CMA V.6.1 and CMA Oligo V6 were shown to be
qualitatively comparable, allowing for cross comparison analysis
[21]. One unique DNA reference served as a control for CMA
analysis and was from a pregnancy-proven fertile, gender-matched
individual without any familial history of congenital genitourinary
defects. CMA procedures and data analyses were performed as
previously described [19,20,21].
All data are MIAME compliant and have been deposited in a
MIAME compliant database.
Interpretation of CNV significance
Clinically significant CNVs included detection of well-charac-
terized deletion/duplication syndromes, deletion/duplication
.3 Mb in size or cytogenetically visible, and de novo deletions or
duplications ,1 Mb. Imbalances that were not associated with
well-characterized human syndromes were defined as ‘‘likely
benign’’ when the variant was well documented to occur in the
normal population on the basis of public databases (http://
projects.tcag.ca/variation) or internal lab experience which
includes analysis of about 16,000 individuals. In cases in which
non-polymorphic defects were ,1 Mb in size and parental
samples were unavailable, variants were considered to be CNVs
of uncertain clinical significance. Maternally inherited copy
changes were included in this latter category as the rearrange-
ments may be causative without necessarily translating into similar
abnormal GU traits in the female genitourinary tract.
CNV confirmation
FISH analysis was used to validate selected CMA findings
.150 Kb in size, using the standard clinical cytogenetics
laboratory protocol [22]. Briefly, BAC clone DNA probes were
labeled directly with Spectrum Orange-dUTP or Spectrum
Green-dUTP using a commercially available kit (Abbot Molecu-
lar/Vysis). At least 10 metaphase and/or 50 interphase cells were
scored for each hybridization. A control probe, labeled in the
opposite color, was included in the same hybridization in order to
confirm that cells were diploid (ploidy control).
Quantitative TaqMan copy number variant (CNV) assays
(Applied Biosystems) were used as an alternate secondary con-
firmation to FISH analysis. All reactions with TaqMan CNV
assays were performed in triplicate using the FAM dye label-based
assay for the target of interest and the VIC dye label-based
TaqMan CNV RNaseP for the internal controls. The targets were
custom designed in the areas where most significant changes in the
probes were detected. QPCR was performed with 20 ng gDNA
according to the manufacturer’s protocol in an Applied Biosystems
One Step Plus Real-Time PCR System using the default universal
cycling conditions. Relative quantitation analysis was done to
estimate copy number for each sample by using the Copy Caller
Software V1.0 (Applied Biosystems).
Concurrent G-banding Karyotype
Metaphase preparations from PHA-stimulated patient lympho-
cyte cultures followed a standard protocol to obtain chromosomes
at $600–50-band level [23]. Briefly, after being cultured for
,72 hours in RPMI 1640 with 20% fetal bovine serum,
lymphocytes were synchronized by the addition of thymidine for
24 hours of culture, followed by the addition of ethidium bromide
and colcemid for the last 45 minutes and 25 minutes of culture,
respectively. The cells were treated for 20 minutes with 0.075 M
KCl and were fixed in 3:1 methanol–acetic acid prior to staining.
Structural Variation and Urogenital Development
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spreads were examined.
Statistical Analysis
To analyze the frequency of de novo copy number changes in
affected GU patients compared to unaffected GU individuals (non-
GU controls), two-tailed Fisher’s exact test was performed and
statistical significance determined using SPSS software. Since (i) de
novo events were only observed in GU patients run on CMA V.6.1
and CMA Oligo V6 (n=90 out of the total of 116 analyzed GU
children) and (ii) data acquired from the array platforms CMA
V.6.1 and CMA Oligo V6 were shown to be qualitatively
comparable [21], comparison of frequencies was done for cases
and non-GU controls run only on CMA V.6.1 and CMA Oligo
V6. P values were also determined for each of the spontaneous
events to evaluate their association with the GU phenotype as
compared to their specific occurrence in individuals without GU
defects (n=8951). Significance threshold was set at P=5.0610
22.
Results
Detection of Non-Polymorphic Imbalances Leading to
Variations in Copy Number in the Genome of Children
Born With Disorders of Sex Development
High molecular weight genomic DNA was isolated from
peripheral blood of 116 children presenting with unexplained
cases of disorders of sexual development ranging in severity from
penile growth or testicular descent anomalies to genitalia
ambiguity or complete sex reversal. Since the primary goal of
this study was to improve the diagnosis of these urogenital defects
and rapidly translate the findings to the clinic, DNA was analyzed
using an established CGH microarray platform available for
clinical diagnosis (chromosome microarray assay, CMA) [19,20].
This targeted array specifically assesses relative copy number
changes for over 150 human clinically relevant chromosomal loci.
One unique DNA reference served as a control for CMA analysis
and was from a pregnancy-proven fertile, gender-matched
individual without any familial history of congenital genitourinary
defects. Copy number variants (CNVs) were classified based on
their clinical significance (see Methods). Basically, CNV pathoge-
nicity depended on whether a given CNV overlapped with a
known genomic syndrome that includes urogenital defects among
the clinical features, or was present in a patient with similar
phenotype, was not a copy number variant in healthy individuals,
arose de novo (but not exclusively) and contained at least one gene.
Chromosomal imbalances were detected in 37 (31.9%) of the
116 patients analyzed (Table 1). When compared to the
polymorphisms documented in public CNV databases (http://
projects.tcag.ca/variation) or based on internal lab experience,
which included analysis of about 16,000 individuals, 83.8% (31 of
37) of these defects were non-polymorphic (Table 1). FISH or
qPCR secondarily validated these structural variants. They
spanned the genome and affected sex chromosomes, as well as
autosomal regions (Figure 1 and Tables 2–5), an observation
consistent with the fact that male sexual development is governed
by genes not restricted to the Y chromosome [7]. Most of the
genomic rearrangements (25 of 37 i.e. 72.9%) were clinically
significant copy number variants (Table 1 and Tables 2–4).
Detection rates of these clinically relevant aberrations were slightly
comparable between the three studied genital conditions (25% for
ambiguous genitalia, 17.2% for hypospadias and 18.5% for
cryptorchidism) (Table 1). Interestingly, these genomic abnor-
malities were noted in patients presenting with both syndromic, as
well as non-syndromic genitourinary disorders (Table 1), with no
Table 1. Submicroscopic imbalances revealed by CMA screening of children affected with syndromic and non-syndromic
disorders of sex development.
No Aberration Chromosomal Aberrations Total
Rate of Detection
of Non-Poly
morphic CNV (%)
Rate of Detection
of Clinically
Significant CNV
(%)
Normal
Benign
CNV Non-Polymorphic CNV
Clinically
Significant UCS
Ambiguous Genitalia
Isolated cases 21 3 11 1 36 33.3 27.8
Associated with other anomalies 18 1 4 1 24 20.8 16.0
Total 39 4 15 2 60 28.3 25.0
Hypospadias
Isolated cases 12 0 3 2 17 29.4 17.7
Associated with other anomalies 8 1 2 1 12 25.0 16.7
Total 20 1 5 3 29 27.6 17.2
Cryptorchidism
Isolated cases 15 0 2 0 17 11.8 11.8
Associated with other anomalies 5 1 3 1 10 40.0 30.0
Total 20 1 5 1 27 22.2 18.5
Total 79 6 25 6 116 26.7 21.5
Footnote: UCS: Uncertain Clinical Significance.
doi:10.1371/journal.pone.0015392.t001
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From a clinical perspective, this latter observation stresses the
importance of screening children presenting with isolated
hypospadias or cryptorchidism, who usually are not referred for
genetic testing.
Regardless of the GU condition, the size of CMA detected
anomalies ranged from 50 kilobases to 57.4 Mb with an average
defect size of 5.5 Mb, which is at the limit of the resolution of
routine karyotype (Tables 2–5). Importantly, none of the
imbalances smaller than 5 Mb, which represent about 70% of
the identified CMA defects, were detected by concurrent high-
resolution karyotype analysis (Tables 2–5). For the cases of
imbalances larger than 5 Mb, CMA analysis had proven to
provide a better definition of the structural defect than the
karyotype (patients 6, 9, 12, 13, 18- see Tables 2–5). Moreover,
most of the detected imbalances (70.6%) were subtelomeric defects
(Tables 2–5), which are known to be difficult to characterize by G-
banding due to their location in the distal G-negative staining
regions of the chromosomes. The most illustrative finding was seen
in patient 15 with a referring diagnosis of ambiguous genitalia
(Table 2). A large deletion of 57.4 Mb spanning the subtelomeric
10q26 was only suspected by karyotype, but was successfully
detected by CMA analysis. Interestingly, this deletion encom-
passed FGFR2, a particularly noteworthy candidate gene in light of
recent studies in rodents that found evidence for its role in testis
formation and male sex determination [24,25]. While gene
variants of FGFR2 may influence the risk of hypospadias in
humans [26], conditional inactivation of FGFR2 in mouse models
resulted in blockade of the XY-specific gonad growth and
disruption of testis differentiation, leading to a male-to-female
sex reversal phenotype. The characterization of FGFR2 as a sex-
determining gene in the mouse suggests that the CMA detected
human haploinsufficiency of FGFR2 is a strong candidate defect
underlying the phenotype of abnormal male genital development
in patient 15.
Interestingly, in three unrelated CMA screened patients (27, 28
and 30; Table 2), a low-level mosaic state became apparent after
CMA screening and retrospective analysis of the karyotype.
Figure 1. Comprehensive map of non-polymorphic copy number changes detected by CMA in patients with disorders of sex
development. On the right, CMA detected imbalances were shown for each clinical condition (asterisks). To gain insight into the genomic
distribution of the identified imbalances, all published single gene mutations associated with cryptorchidism (blue), hypospadias (green) and
ambiguous genitalia (red) were reviewed and indicated on the left side of the chromosomes. References are available upon request.
doi:10.1371/journal.pone.0015392.g001
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e15392Interphase FISH performed on blood smears in which multiple
cell lineages coexist, was requested after CMA testing, to verify
mosaicism in these children. The conventional karyotype was
normal since it examined only the cell population of stimulated T
lymphocytes. The fact that CMA analysis performed on DNA
from uncultured blood cells was able to improve the detection of
low level mosaicism missed by cytogenetic analysis, is of significant
clinical importance, especially for the diagnosis of genital
ambiguity.
Strong Association of De Novo Copy Variants with
Human Disorders of Sex Development
The inheritance of the FISH-confirmed CMA defects was
investigated by CMA testing. Parental samples were not available
for all patients, leading to an underestimation of the clinically
significant abnormalities in the present evaluation. De novo
occurrences were noted for: (i) deletions in 1p36.33, 9p23p24
and 19q12-q13.11 for probands presenting with a referring
diagnosis of ambiguous genitalia; (ii) duplications in 10p14 and
Xq28 for cryptorchid children; (iii) and deletions in 12p13.31-
p13.2 and 16p11.2 for patients with hypospadias (Table 6).
Importantly, these de novo copy number changes were found to be
more frequent in patients with congenital genitourinary defects
than in control individuals without GU abnormalities (28 out of
8951), with an association that is statistically significant
(P=6.08610
212; Fisher’s exact test) (Tables 6 and 7).
To a lesser extent, imbalances inherited from a phenotypically
normal maternal parent were also considered since the rearrange-
ments may be causative without necessarily translating into similar
abnormal GU traits in the female genitourinary tract. Thus,
maternally inherited copy changes were considered as of unclear
clinical significance and noted as: (i) deletion in 7p22.1 for
ambiguous genitalia; (ii) duplications in 4q35.2 and 5p15.31 for
hypospadias; (iii) duplication in 5p15.2 and in the androgen
receptor insensitivity region, Xq12 for cryptorchidism (Table 5).
Hence, the present analysis shed light on spontaneous
chromosomal rearrangements affecting novel and unsuspected
gene-enriched regions that have potential to contribute to the
pathogenesis of human genital development.
Unrelated Patients Presenting with Similar Genital Traits
Shared Common Affected Loci
The causal link of the CMA defects to the GU phenotype was
further strengthened by the fact that common overlapped loci
were shared by unrelated probands having similar genital
defects. Spontaneous deletion of the 9p23p24 region was found
in patients 9, 12, and 13, all with gonadal dysgenesis (Table 2).
A minimal common region of overlap included 260 kb of
9p24.3 (Figure 2A). This smallest reported sex-reversing 9p
deletion appears therefore as a hotspot for the pathogenesis of
sex determination. It encompasses KANK1, DOCK8 and DMRT
genes. The testis specific DMRT1 is worthy of mention, since it
encodes a protein-sharing domain homology with the doublesex
(Dsx)o fDrosophila and Mab3 of Caenorhabditis. Both of these genes
a r ec r u c i a lf o rt h en o r m a ls e x u a ld e v e l o p m e n to ft h e s e
organisms. Genetic inactivation of DMRT1 demonstrated its
requirement for the development of the male gonad [27], but
did not lead to sex reversal in XY mice, suggesting the
involvement of additional interacting factors in order to
phenocopy the human phenotype. One of such gene candidates
could be KANK1 since it is highly expressed in the mouse
embryonic genital tract (http://www.genepaint.org) and is able
to physically interact and regulate the subcellular localization of
beta catenin whose activation in normal XY mice has been
shown to disrupt the male program and result in male-to-female
sex-reversal [28,29].
Table 6. De novo clinically relevant copy number changes detected in patients presenting with disorders of sex development
(DSD).
ID Locus DSD diagnosis CNV
Start
Position
Size
(Mb) Genes
%I n
Non-GU
%I n
GU P value Karyotype Inh
17 12p13.31p13.2 Hypospadias Loss 7,987,984 2.306 65 0.01 1.11 1.9610
22 46,XY dn
20 16p11.2 Hypospadias Loss 29,729,970 0.131 10 0.07 1.11 5.7610
22 46,XY dn
34 Xq28 Hypospadias Gain 154,703,321 0.158 1 0 2.22 9.9610
23 46,XY dn
33 Xq28 Cryptorchidism Gain 154,703,321 0.158 1 0 2.22 9.9610
23 46,XY dn
16 10p14 Cryptorchidism Gain 12,011,806 0.064 3 0.02 1.11 2.9610
22 n/a dn
1 1p36.33 Ambiguous Genitalia Loss 799,476 1.257 65 0.17 1.11 1.4610
21 46,XX dn
12 9p23p24.3 Ambiguous Genitalia
(Gonadal dysgenesis)
Loss 356,238 9.774 66 0.04 2.22 1.4610
23 46,XY,der(9)
del(9)(p23)dup
(9)(p23p12)
dn
13 9p24.1-pter Ambiguous Genitalia
(Gonadal dysgenesis)
Loss 1 6.785 58 0.04 2.22 1.4610
23 46,XY,der(9)
del(9)(p24pter)
dup(9)(p23p12)
dn
9 9p24.3 Ambiguous Genitalia
(Gonadal Dysgenesis)
Loss 356,238 0.259 4 0.04 2.22 1.4610
23 46,XY,del(9)
(p23)
dn
22 19q12q13.11 Ambiguous Genitalia Loss 33,828,527 5.638 49 0 1.11 9.9610
23 46,XY dn
Footnotes:
Minimal size of the spontaneous aberrations (Mb) and the number of the encompassing HGNC (Hugo Gene Nomenclature Committee) genes (G) (NCBI Build v35.1)
were indicated.
P values were based on two-tailed Fisher’s exact test comparing the frequency of each spontaneous event in cases versus controls. Significance threshold was set at
P=5.0 610
22.
Abbreviations: Inh: Inheritance, dn: de novo.
doi:10.1371/journal.pone.0015392.t006
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e15392In addition to the 9p region, the locus Yp11.31 was an expected
recurrent hit in patients with ambiguous genitalia, since it
encompasses SRY, the testis-determining gene (Table 2).
Unique Similar Loci were Abnormal in Patients
Presenting with Different Urogenital Traits
Identical unique loci were affected in patients presenting distinct
genital phenotypic traits, which suggest that structural perturba-
tions within these segments may alter master regulator(s) of
multiple processes of human sexual development. Indeed, a large
deletion of the subtelomeric cytoband 5p15 detected in the patient
6 with genital ambiguity overlapped a region duplicated in patient
5 with hypospadias (Figure 2B). The fact that the shared genomic
interval spanned the locus of the Cri-du-Chat syndrome, which
includes hypospadias among its various clinical features, provides
support for a causative link of the 5p15 defect to the GU
phenotype. The encompassed gene, ADCY2, appeared as an ideal
candidate controlling genitourinary development since it presents
a high and specific expression pattern in the testis as well as in the
developing genital tract (http://www.genepaint.org). Moreover,
the ADCY2 encoding protein regulates the intracellular levels of
cyclic AMP, a crucial second messenger in major regulatory
pathways involved in the biogenesis of the genital system such as
Sonic Hedgehog signaling.
The DiGeorge syndrome critical region 22q11.2 was also found
duplicated in patients with ambiguous genitalia, while its deletion
was seen in patients presenting with GU abnormalities in
association with Smith-Lemli-Opitz syndrome or Wilms tumor
(Table 2). This region may have a dosage sensitive gene(s) that
plays a role in the development of the genitourinary system in
humans.
In parallel, alterations occurring on 2q22 and Xq28 loci were
found in patients with cryptochidism and hypospadias (Tables
3–4). These genomic regions may contain candidate genes that
regulate a common protagonist(s) or pathway(s) controlling both
testicular descent and formation of the male urethra. The deletion
2q22 in patient 2 presenting with cryptorchidism and hypospadias
was in the region associated with Mowat-Wilson syndrome
(MWS). Among anomalies frequently observed in MWS are
urogenital anomalies including hypospadias and undescended
testis. MWS is a genetic condition caused by heterozygous
mutations or deletions of ZEB2 (zinc finger E-box binding
homeobox 2 gene), a protein that interacts with a receptor-
mediated, activated full-length SMAD. ZEB2 is strongly expressed
in the developing murine genital tract (http://www.genepaint.
org). Knockout mice models of ZEB2 presented reproductive
system defects ([30], http://www.informatics.jax.org). Moreover,
ZEB2 has been shown to modulate Wnt signaling, a critical
pathway for the development of the genital tract [31]. Hence,
ZEB2 appears as a potential candidate involved in the male
urogenital development.
Taken together, our findings highlight for the first time the
presence of previously unrecognized chromosomal imbalances as
potential genetic risks factors in disorders of sexual development
and illustrate how a microarray-based technology provides a
powerful alternative to traditional cytogenetic and gene-mapping
approaches for discovering contributing factors in disease of
complex etiology.
Discussion
The development of male reproductive system is a complex
process controlled by delicate networks that specify sex-specific
differentiation, organogenesis and endocrine function. The
fragility of these regulatory cascades is illustrated by the high
prevalence of genitourinary defects in newborns. These inborn
urogenital anomalies present difficult challenges for the parents
and the physicians, as care of these children is complicated by
surgical, psychological, social and sexual concerns. The gold
standard for genetic diagnosis remains a karyotype analysis and an
endocrine profile but findings in intersex cases are not always
informative. Indeed, only a small portion of these developmental
aberrations can be attributed to defects in the synthesis of
testosterone or adrenal steroid hormones, receptor alterations,
exogenous modifiers or obvious numerical and structural chro-
mosomal alterations, such as Klinefelter syndrome. The underly-
ing causes of the majority of ‘‘idiopathic’’ cases remain to be
discovered. In this study, the use of a clinically validated
microarray (CMA) revealed the existence of cryptic imbalances
strongly associated with defects of urogenital development or
recurrently found in patients with DSD. These chromosomal
aberrations were mostly too small to be detected by the routinely
ordered karyotype, which has a limited resolution of 5–10 Mb,
depending on the quality of chromosome preparations. Many of
these genomic anomalies went also largely undetected because
they were located in subtelomeric loci, which are notoriously
difficult to characterize by G-banding. Moreover, mild or isolated
cases of hypospadias and cryptorchid patients are usually not
referred for genetic testing, while this study proved that this subset
of patients harbored structural variation that may convey defective
urogenital traits.
Most of the detected chromosomal aberrations encompassed
one to a few hundred genes including known gonad-determining
genes (SRY and DMRT1) as well as novel candidate genes such as
FGFR2, KANK1, ADCY2 and ZEB2. Changes in dosage or
structure of genes within the affected DNA segments might lead
to haploinsufficiency or altered transcription profiles, which may
disturb the intricate fine-tuned network of genes controlling the
human genital development. Clinically relevant examples of gene
dosage alterations have already been documented for factors
controlling mammalian sex development. For instance, deletion of
the sex-determining gene WNT4 is responsible for the masculin-
ization of XX mouse pups, while its duplication and overexpres-
sion in humans leads to XY sex reversal [32,33]. Duplications of
large segments of DNA containing DAX1 or SOX9 also cause sex
reversal [34,35]. Thus, our findings contribute in a coherent
manner to strengthen the emerging concept that sex determina-
tion and differentiation are dosage sensitive at multiple steps of
their pathways. In addition to dosage effects, imbalances may lead
Table 7. De novo CMA detected events are more enriched in
GU patients than in individuals without urogenital
abnormalities.
Sample Group
Total
Patients*
Patients with
de novo
events Ratio P value
Genitourinary Defects 90 10 0.11 6.08610
212
Non-Genitourinary Defects 8951 28 0.003
Footnotes: Two-tailed Fisher’s exact test was used to evaluate the association of
CMA detected de novo events with urogenital defects. *: GU cases (n=90 out of
the total of 116 analyzed GU children) and non GU controls (n=8951) run only
on CMA V.6.1 and CMA Oligo V6, since de novo events were specifically
observed in GU patients screened with these two qualitatively comparable
platforms (n=10; see Table 6); [21]. See Statistical Analysis in Methods for
details.
doi:10.1371/journal.pone.0015392.t007
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e15392Figure 2. Overlapping Chromosomal Rearrangements in DSD patients. A. Delineation of a minimal human 9p sex reversal deletion.
Schematic representation of the overlapping CMA detected 9p deletions in three unrelated 46,XY patients presenting with gonadal dysgenesis. A
minimal common 260 Kb region was defined. Map showing the BAC clones covering the critical sex determination region and the normal flanking
clones (RP11-459D20 and GS-43N6). A UCSC genome browser view (May 2006 Human Assembly) of the RefSeq genes encompassing the minimal
9p24.3 sex-reversing region was presented. B. Structural variation shared by unrelated patients presenting with distinct urogenital
defects, may affect master regulator(s) of human genital development. A common genomic interval of 65 Kb in the cytoband 5p15.31 was
deleted in patient 6 with genital ambiguity and duplicated in patient 5 with hypospadias. CMA detection of the 65 Kb duplication in patient 5 and a
UCSC genome browser view (May 2006 Human Assembly) of the encompassed ADCY2 gene were presented.
doi:10.1371/journal.pone.0015392.g002
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PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e15392to disruption of regulatory sequences that control the expression of
neighboring genes; thus, in some cases, a gene related to genital
development may lie adjacent to the detected deletion or
duplication. For instance, a submicroscopic 258 Kb deletion,
detected 11,320 bp upstream of DAX1 in a 21-year-old 46,XY
female, may lead to a loss of regulatory sequences and position-
effect upregulation of DAX1 expression [36].
Our findings provide support for the genomic basis of human
disorders of sexual development and call for genome-wide CNV
screenings which may, due to their extended coverage, reveal a
higher proportion of germline mutations associated with urogen-
ital defects. Enrichment in candidate genes for human sexual
development is subsequently bound to increase. Our present study
using the clinically established CMA platform was motivated by a
rapid translation of our findings to the clinical arena. Molecular
testing, such as with CMA, could significantly impact patient care
by assisting the pediatric urologists and neonatologists in diagnosis.
Genetic counseling offered to families based on the identification
of pathogenic rearrangements may provide parents with essential
clinical information pertaining to the child’s diagnosis and permit
proper estimates of the risk of recurrence for subsequent
pregnancies. De novo imbalances are expected to have a very low
risk of recurrence but it may be useful in future pregnancies to
check for gonadal mosaicism in the parents. An unbalanced
translocation identified by CMA may reveal a balanced translo-
cation in a carrier parent and thus chances for a chromosomally
abnormal future pregnancy would be as high as 25%. In vitro
fertilization and pre-implantation genetic diagnosis could provide
these couples with a possible alternative path to parenthood,
specifically in case of severe genital ambiguity.
In conclusion, this study presented structural DNA variation as
a potential underlying etiology for human disorders of sexual
development. Frequent disease-causing submicroscopic gains and
losses of DNA segments were detected across the genome and
strongly associated with defective urogenital traits. This has been
achieved with significantly higher resolution and greater clinical
yield than standard routine karyotype, thus making this array-
based CGH screen as a genetic test of choice in diagnosis. While
GU defects cases arise among newborns without clear etiology,
this study offers novel loci to dissect for determining key genes
involved in the human sexual development.
Acknowledgments
We would like to thank all the referring physicians and especially Drs.
Edmond T. Gonzales, Lars Cisek, David R. Roth and Eric Jones, the
affected individuals and their family members who participated in this
study. We thank Dr. Kenneth McElreavy (Pasteur Institute, Paris, France)
who provided two patient samples with gonadal dysgenesis for this study.
We thank Drs. John Belmont, Lisa White and Hao Liu for their
cooperation. We also thank Matthew Folsom for his excellent technical
assistance.
Author Contributions
Conceived and designed the experiments: MTL SH DJL. Performed the
experiments: MTL SH STC SY LM JFL. Analyzed the data: MTL SH
DJL JFL. Contributed reagents/materials/analysis tools: CAS SHK SWC.
Wrote the paper: MTL.
References
1. Virtanen HE, Bjerknes R, Cortes D, Jorgensen N, Rajpert-De Meyts E, et al.
(2007) Cryptorchidism: classification, prevalence and long-term consequences.
Acta Paediatr 96: 611–616.
2. Pohl HG, Joyce GF, Wise M, Cilento BG, Jr. (2007) Cryptorchidism and
hypospadias. J Urol 177: 1646–1651.
3. Hughes IA (2007) Early management and gender assignment in disorders of
sexual differentiation. Endocr Dev 11: 47–57.
4. Foresta C, Zuccarello D, Garolla A, Ferlin A (2008) Role of hormones, genes,
and environment in human cryptorchidism. Endocr Rev 29: 560–580.
5. Wang MH, Baskin LS (2008) Endocrine disruptors, genital development, and
hypospadias. J Androl 29: 499–505.
6. Matzuk MM, Lamb DJ (2008) The biology of infertility: research advances and
clinical challenges. Nat Med 14: 1197–1213.
7. Wilhelm D, Koopman P (2006) The makings of maleness: towards an integrated
view of male sexual development. Nat Rev Genet 7: 620–631.
8. Cox MJ, Coplen DE, Austin PF (2008) The incidence of disorders of sexual
differentiation and chromosomal abnormalities of cryptorchidism and hypospa-
dias stratified by meatal location. J Urol 180: 2649–2652. discussion 2652.
9. Moreno-Garcia M, Miranda EB (2002) Chromosomal anomalies in cryptorchi-
dism and hypospadias. J Urol 168: 2170–2172. discussion 2172.
10. Wain LV, Armour JA, Tobin MD (2009) Genomic copy number variation,
human health, and disease. Lancet 374: 340–350.
11. Lupski JR (2007) Genomic rearrangements and sporadic disease. Nat Genet 39:
S43–47.
12. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, et al. (2006)
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with
developmental delay and learning disability. Nat Genet 38: 1032–1037.
13. Sharp AJ, Hansen S, Selzer RR, Cheng Z, Regan R, et al. (2006) Discovery of
previously unidentified genomic disorders from the duplication architecture of
the human genome. Nat Genet 38: 1038–1042.
14. Koolen DA, Vissers LE, Pfundt R, de Leeuw N, Knight SJ, et al. (2006) A new
chromosome 17q21.31 microdeletion syndrome associated with a common
inversion polymorphism. Nat Genet 38: 999–1001.
15. Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, et al.
(2004) Mutations in a new member of the chromodomain gene family cause
CHARGE syndrome. Nat Genet 36: 955–957.
16. Ballif BC, Hornor SA, Jenkins E, Madan-Khetarpal S, Surti U, et al. (2007)
Discovery of a previously unrecognized microdeletion syndrome of 16p11.2-
p12.2. Nat Genet 39: 1071–1073.
17. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, et al. (2006) Copy
number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and
humans. Nature 439: 851–855.
18. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al. (2005) The
influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS
susceptibility. Science 307: 1434–1440.
19. Cheung SW, Shaw CA, Yu W, Li J, Ou Z, et al. (2005) Development and
validation of a CGH microarray for clinical cytogenetic diagnosis. Genet Med 7:
422–432.
20. Lu X, Shaw CA, Patel A, Li J, Cooper ML, et al. (2007) Clinical implementation
of chromosomal microarray analysis: summary of 2513 postnatal cases. PLoS
ONE 2: e327.
21. Ou Z, Kang SH, Shaw CA, Carmack CE, White LD, et al. (2008) Bacterial
artificial chromosome-emulation oligonucleotide arrays for targeted clinical
array-comparative genomic hybridization analyses. Genet Med 10: 278–289.
22. Lu XY, Phung MT, Shaw CA, Pham K, Neil SE, et al. (2008) Genomic
imbalances in neonates with birth defects: high detection rates by using
chromosomal microarray analysis. Pediatrics 122: 1310–1318.
23. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR (1997) Diagnosis of CMT1A
duplications and HNPP deletions by interphase FISH: implications for testing in
the cytogenetics laboratory. Am J Med Genet 69: 325–331.
24. Bagheri-Fam S, Sim H, Bernard P, Jayakody I, Taketo MM, et al. (2008) Loss of
Fgfr2 leads to partial XY sex reversal. Dev Biol 314: 71–83.
25. Kim Y, Bingham N, Sekido R, Parker KL, Lovell-Badge R, et al. (2007)
Fibroblast growth factor receptor 2 regulates proliferation and Sertoli
differentiation during male sex determination. Proc Natl Acad Sci U S A 104:
16558–16563.
26. Beleza-Meireles A, Lundberg F, Lagerstedt K, Zhou X, Omrani D, et al. (2007)
FGFR2, FGF8, FGF10 and BMP7 as candidate genes for hypospadias.
Eur J Hum Genet 15: 405–410.
27. Raymond CS, Murphy MW, O’Sullivan MG, Bardwell VJ, Zarkower D (2000)
Dmrt1, a gene related to worm and fly sexual regulators, is required for
mammalian testis differentiation. Genes Dev 14: 2587–2595.
28. Wang Y, Kakinuma N, Zhu Y, Kiyama R (2006) Nucleo-cytoplasmic shuttling
of human Kank protein accompanies intracellular translocation of beta-catenin.
J Cell Sci 119: 4002–4010.
29. Maatouk DM, DiNapoli L, Alvers A, Parker KL, Taketo MM, et al. (2008)
Stabilization of beta-catenin in XY gonads causes male-to-female sex-reversal.
Hum Mol Genet 17: 2949–2955.
30. Higashi Y, Maruhashi M, Nelles L, Van de Putte T, Verschueren K, et al. (2002)
Generation of the floxed allele of the SIP1 (Smad-interacting protein 1) gene for
Cre-mediated conditional knockout in the mouse. Genesis 32: 82–84.
31. Miquelajauregui A, Van de Putte T, Polyakov A, Nityanandam A, Boppana S,
et al. (2007) Smad-interacting protein-1 (Zfhx1b) acts upstream of Wnt signaling
in the mouse hippocampus and controls its formation. Proc Natl Acad Sci U S A
104: 12919–12924.
Structural Variation and Urogenital Development
PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e1539232. Jordan BK, Mohammed M, Ching ST, Delot E, Chen XN, et al. (2001) Up-
regulation of WNT-4 signaling and dosage-sensitive sex reversal in humans.
Am J Hum Genet 68: 1102–1109.
33. Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, et al. (2003)
Endothelial and steroidogenic cell migration are regulated by WNT4 in the
developing mammalian gonad. Development 130: 3663–3670.
34. Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, et al. (1994) A dosage
sensitive locus at chromosome Xp21 is involved in male to female sex reversal.
Nat Genet 7: 497–501.
35. Huang B, Wang S, Ning Y, Lamb AN, Bartley J (1999) Autosomal XX sex
reversal caused by duplication of SOX9. Am J Med Genet 87: 349–353.
36. Smyk M, Berg JS, Pursley A, Curtis FK, Fernandez BA, et al. (2007) Male-to-
female sex reversal associated with an approximately 250 kb deletion upstream
of NR0B1 (DAX1). Hum Genet 122: 63–70.
Structural Variation and Urogenital Development
PLoS ONE | www.plosone.org 13 October 2010 | Volume 5 | Issue 10 | e15392